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Systematic Review: Does Continuous Positive Airway Pressure (CPAP) treatment of 
Obstructive Sleep Apnoea (OSA) improve asthma-related clinical outcomes?  
 
 
Introduction: A high prevalence of OSA has been observed in asthma populations, with 
detrimental impact on clinical outcomes.  
Aim:  To determine if CPAP treatment of co-existing OSA improves asthma-related 
symptoms and quality of lifeMethods: Literature review of EMBASE and MEDLINE databases 
prior to July 2017. Study populations included asthmatics with co-existing OSA treated with 
CPAP, and ≥ 1 asthma-related clinical outcome measure 
Results: 12 studies; 8 prospective quasi-experimental and 4 observational. Mean CPAP 
duration;19.5(2-100) weeks. Meta-analysis demonstrated significant improvement in mean 
Asthma Quality of Life Questionnaire scores (AQLQ and mini-AQLQ); 0.59 (95%CI; 0.25, 
0.92), p=0.0006. No significant improvement was demonstrated in forced expiratory volume 
in one second (FEV1)%predicted; 0.32 (95%CI; -2.84, 3.47), p=0.84. Asthma Control 
Test/Asthma Control Questionnaire improved in 2 studies, with no improvement in 1 study. 
4 studies demonstrated improvement in asthma daytime/night-time symptoms, and 3 
studies showed improved asthma severity.  
Conclusion: Asthmatics with co-existing OSA can experience improved quality of life 
with CPAP treatment. This effect appears more pronounced in severe OSA or poorly 
controlled asthma. 
 
 
 
 
 
 
 
Introduction 
An overlap between asthma and OSA is increasingly recognised. Epidemiological studies 
have shown asthmatics are more likely to report symptoms of sleep disordered breathing 
such as excessive daytime sleepiness, snoring and apnoeas
1
. Polysomnography (PSG) has 
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been used to demonstrate a high prevalence of OSA in asthma
2
.  Approximately 5-10% of 
asthmatics have severe or difficult to treat asthma (SDTA) that remains problematic despite 
optimal treatment
3
. The prevalence of OSA has been reported to be as high as 95% in severe 
steroid dependent asthma
2
 and OSA can adversely impact asthma control
1
. Continuous 
Positive Airway Pressure (CPAP) is the gold standard treatment for patients with the OSA 
syndrome
4
, however the efficacy of this treatment in terms of impact on co-existing asthma 
symptoms remains unclear.  
 
The mechanisms through which asthma and OSA might interact are complex. Bronchial 
hyperresponsiveness and airway inflammation are the two key pathophysiological hallmarks 
of asthma
5
.  Studies have also demonstrated that increased airway and systemic 
inflammation are present in patients with OSA
6,7
. Additionally, CPAP treatment can reduce 
Fractional Exhaled Nitric Oxide (FENO)
6
 and improve markers of systemic inflammation such 
as C-reactive protein (CRP)
7
. Whether CPAP improves bronchial hyperresponsivness in OSA 
patients is less clear
8,9
. 
 
Asthma and OSA have common co-morbidities that include obesity and gastro-oesophageal 
reflux disease (GORD). These co-morbidities can negatively impact on asthma control
7
. 
GORD can be precipitated by the large negative intrapleural pressure swings that occur in 
OSA
7
, and CPAP treatment has been shown to improve reflux symptoms
10
. CPAP has also 
been shown to improve insulin resistance
11
, which could potentiate weight loss and improve 
asthma symptoms.  The mechanisms through which CPAP could potentially improve asthma 
symptoms are illustrated in figure 1. 
 
A high prevalence of OSA has been observed in asthma populations, with negative impact 
on asthma symptoms and control. CPAP is known to be an effective treatment for OSA in 
the general population. However, there are reports of patients developing bronchial 
hyperresponsiveness with CPAP treatment
9
 which could clearly have a detrimental impact 
on asthmatic patients. The aim of this review is to ascertain the effects of CPAP on 
asthmatic patients with OSA, its tolerability and in particular its impact on asthma-related  
symptoms and quality of life. 
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Methods 
This systematic review is registered with PROSPERO (CRD 42017074054). Standard 
systematic review methodology was used. 
 
Aims 
To determine if CPAP treatment of co-existing OSA improves - asthma-related quality of life, 
symptoms and other related clinical outcomes  
 
Inclusion & exclusion criteria 
To be included in this review, studies had to meet the following criteria: 
1) A population of asthmatics with co-existing obstructive sleep apnoea. Studies with mixed 
populations were included if data for asthmatics with co-existing OSA were presented 
separately.  
2) Treatment with CPAP 
3) Measurement of ≥ 1 asthma-related clinical outcome 
 
Studies were excluded based on the following criteria: 
1) Not written in English 
2) Non-adult populations (<18 years) 
3) Full text article not available (ie. abstracts, letters, and editorials) 
4) Original research/data not included in published article 
 
Search Methodology  
Literature search was performed using EMBASE and MEDLINE databases. The search terms 
included “asthma OR asthmatic” AND “obstructive sleep apnoea/apnea OR OSA” AND 
“continuous positive airway pressure OR CPAP”. All studies up to and including July 2017 
were included.  
 
Data Extraction & Assessment of Bias 
Two independent reviewers assessed the results of the searches generated in EMBASE and 
MEDLINE databases. Studies generated from the above searches were assessed as per the 
PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analysis) diagram 
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(figure 2) and reviewed in accordance with the inclusion/exclusion criteria, with any 
disagreements between the reviewers resolved through discussion.  
The reviewers assessed each study to identify if ≥ 1 asthma-related clinical outcome was 
measured. Clinical outcomes included; the Asthma Control Test (ACT), Asthma Control 
Questionnaire (ACQ), Asthma Quality of Life Questionnaire (AQLQ) and daytime/night-time 
asthma symptoms Additional outcome measures included; lung function, exacerbation 
frequency, accident and emergency (A&E) visits or hospital admissions, and , any other 
outcomes thought clinically relevant by both reviewers . 
 
Studies were assessed for bias by the two reviewers, with any disagreement resolved 
through discussion. Bias was assessed using the ROBINS-I (Risk of Bias in Non-Randomised 
Studies of Interventions)
12
, which is based on the Cochrane risk of bias tool for randomised 
studies.  
 
Data synthesis and analysis 
Studies were categorised into groups according to the clinical outcome measured; 1) asthma 
quality of life, 2) asthma control/symptoms, 3) asthma severity and 4) lung function and 
physiological measures. 
 
The reviewers judged that there was sufficient data to meta-analyse 1) AQLQ and mini-
AQLQ and 2) lung function; Forced Expiratory Volume in 1 second- % predicted 
(FEV1%pred). RevMan (Review Manager) version 5.3 was used for the meta-analysis. A fixed 
effects model was used to calculate mean difference in pre and post CPAP values for these 
outcome measures. A narrative synthesis was used to describe the remaining data, as 
clinically significant heterogeneity in the measuring of other clinical outcomes precluded 
meta-analysis.  
Results 
12 studies met the inclusion/exclusion criteria for this systematic review as illustrated in the 
PRISMA diagram (figure 2). 8 studies were prospective quasi-experimental studies and 4 
were observational. No randomised, placebo-controlled studies were identified. It is 
important to note that the two cross-sectional studies by Teodorescu et al appear to be 
based on the same cohort of patients. Although the total data set in one paper was reported 
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as enhanced with subjects from an additional centre, in the subset of patients with asthma 
and OSA the numbers included are very similar in both studies (136 versus 140, with 75 
patients in each study using CPAP).  
 
The mean duration of CPAP for the prospective quasi-experimental studies was 19.5 weeks 
(range 2-100 weeks). The duration of CPAP in the cross-sectional or retrospective studies 
ranged from “current treatment” to 5.7 years. There was improved asthma related quality 
of life in two studies when measured using AQLQ or mini-AQLQ (see table 1). Meta-analysis 
of available Asthma Quality of Life data was possible after combining the results of AQLQ 
and mini-AQLQ, which have similar scores and clinical interpretation. 
 
Asthma control was reported in 3 studies; 1 study used the ACQ and demonstrated 
significant improvement post-CPAP, 2 studies used the ACT and 1 demonstrated significant 
improvement, the other did not. 4 further studies evaluated daytime and/or night-time 
asthma symptoms with all 4 reporting improvements with CPAP. 1 study demonstrated a 
non-significant reduction in A&E visits (p=0.058). 1 study found a significant reduction in 
asthma exacerbation frequency with CPAP (p=0.015) (see table 2). 
 
Asthma severity was measured in 3 studies. Methods of measuring severity of asthma 
included GINA (Global Initiative for Asthma) guidelines, NAEPP (National Asthma Education 
and Prevention Program) guidelines and a visual analogue score, with each study using a 
different method. An improvement of asthma severity was seen in all 3 following CPAP 
(table 3). 
 
Bronchial airway responsiveness was assessed in 2 studies. One study used the 
methacholine challenge test and showed no significant improvement with CPAP, the other 
study assessed airway reversibility and demonstrated a significant improvement with CPAP 
(table 4).   
 
6 studies reported changes in FEV1 with CPAP. 2 studies were excluded from meta-analysis 
due to lack of sufficient data or a significant difference in the study design. Four studies 
were combined in a meta-analysis. There was no significant improvement in FEV1 (5 studies) 
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or FEV1/FVC ratio (3 studies). Peak expiratory flow rates improved in the 1 study that 
reported it.  Arterial oxygenation and arterial carbon dioxide levels improved in the 1 study 
that reported this outcome and FENO also improved in 1 study (table 4). 
 
Meta-Analysis 
Mean asthma quality of life scores (AQLQ and mini-AQLQ) improved significantly by 0.59 
(95% CI 0.25, 0.92), p=0.0006 with CPAP. No significant improvement was demonstrated in 
FEV1(%pred); 0.32 (95% CI -2.84, 3.47), p=0.84. These results are illustrated using forest 
plots (figure 3). 
 
Risk of bias 
The potential for bias in each study was assessed using the ROBINS-I scale. A high risk of bias 
due to confounding was present in at least 4/12 studies with unclear evidence in 3/12. 
There was also high risk of selection and misclassification bias in 4/12 studies. The overall 
risk of bias for all 12 studies is illustrated in figure 4 as both a bias graph and bias summary.  
 
Discussion 
This systematic review has included all current literature with regards to the impact of CPAP 
on co-existing asthma in patients with OSA. We found evidence to support the hypothesis 
that CPAP significantly improves asthma-related quality of life. The majority of studies found 
that daytime or night-time asthma symptoms improve with CPAP. However, current 
evidence does not support an improvement in clinically significant asthma control using 
standardised measures such as the ACT or ACQ. CPAP does not improve lung function in this 
meta-analysis, but this finding is of unclear clinical significance in the asthmatic population    
 
The findings of this review are important because a high prevalence of OSA has been 
consistently reported in asthma, particularly within the severe asthma population
2
. Patients 
with severe asthma and co-existing OSA have been shown to have increased sputum 
neutrophil counts and evidence of airway remodelling
13
. Asthma patients with a 
neutrophilic rather than the typical eosinophilic phenotype are less likely to respond to with 
high dose inhaled corticosteroids or oral corticosteroids
13
. This review demonstrates that 
CPAP treatment can improve asthma-related quality of life and symptoms in patients with 
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co-existing asthma and OSA. This has important implications for the screening of asthma 
patients for the presence and the subsequent treatment of OSA, particularly within severe 
or refractory asthma populations.  
 
In five of the twelve studies
14,15,16,17,18
 there was clear evidence of the application of robust 
asthma diagnostic criteria following international guidelines. Asthma severity was measured 
in two of the studies in accordance with current guidelines
19,17
 but one of the studies
20
  used 
patient-reported symptoms via a visual analogue scale. Polysomnography (PSG) is the gold-
standard tool for the diagnosis of OSA and this was the case in eight of the studies. One 
study used limited-channel sleep studies in 70% and PSG in 30% of patients
14
, while one of 
the retrospective reviews used previous home limited-channel sleep study records
20
. Two 
cross-sectional questionnaire-based studies relied on records of a previous OSA diagnosis, 
however no information was provided concerning the diagnostic method used or the OSA 
severity. This raises questions about reliability of OSA diagnosis
19,21
. As previously 
mentioned, these two studies appear to include data from the same study population. 
However, the two studies report different outcomes and have therefore both been reported 
in this review
19,21
.  It was reassuring to note that the majority of studies used PSG for the 
diagnosis of OSA, although limited-channel sleep studies are a well-recognised alternative. 
The duration of CPAP treatment varied between studies and ranged from two weeks to 
twenty-five months for the prospective studies. OSA patients often take longer than a 
month to become fully complaint with CPAP and this could account for differences in results 
seen, particularly as Serrano-Pariente et al demonstrated bigger improvements in both ACQ 
and mini AQLQ at six months when compared to three months of CPAP treatment
14
. Five of 
the twelve studies reported CPAP compliance of at least four hours per night. This is 
generally regarded as the minimum hours of CPAP required to improve sleepiness scores in 
OSA
22
. However the duration of CPAP use per night needed to improve asthma-related 
clinical outcomes is not known. 
 
Asthma-related quality of life is measured using either the validated AQLQ or the 
abbreviated mini-AQLQ. The AQLQ assesses four domains within asthma (symptoms, activity 
limitation, emotional function and environmental stimuli). The AQLQ scale ranges from 0 
(worst) to 7 (best) and a change of 0.5 would signify a clinically meaningful change
23,24,25
. 
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Two of the twelve included studies evaluated asthma-related quality of life and both found 
a clinically significant improvement with CPAP
 15,14
, with study heterogeneity being minimal 
(as shown by the I2 value of 0%; figure 3a). Of note, the duration of CPAP was six weeks in 
the study by Lafond et al compared to six months in the study by Serrano-Pariente et al. 
However, AQLQ takes into account asthma-related quality of life over the preceding four 
weeks and would therefore be appropriate in both studies.  Serrano-Pariente et al 
demonstrated a mean significant improvement of 0.51. However an improvement of 0.5 or 
more was only demonstrated in patients with either moderate-severe asthma (0.61) or 
severe OSA (0.54), and the results failed to reach statistical significance or clinical relevance 
in either mild asthma or mild-moderate OSA
14
. Lafond et al demonstrated a mean 
improvement of 0.8, and this was correlated with both body mass index (BMI) and severity 
of OSA. Severity of asthma was not reported in this study and the AQLQ results were not 
compared between severe OSA and mild-moderate disease
15
.  
 
Asthma control is usually measured using the validated ACT
26
 or ACQ
27
. There was 
significant heterogeneity in the study designs, populations and outcome measures which 
precluded meta-analysis of asthma control scores. Shaarawy et al used a prospective quasi-
experimental study design with robust asthma diagnostic criteria and included a group of 
poorly controlled asthmatics
16
. Conversely, although the study population was much larger 
in the study by Kauppi et al, it was based on retrospective recall of symptoms and ACT pre-
CPAP which was then compared to current ACT. The mean duration of CPAP was more than 
5 years and therefore a significant risk of recall bias is present with this particular study
20
. 
Four studies reported improvements in daytime and/or night-time asthma symptoms using 
different scoring systems or visual analogue scores, but without reporting formal ACT/ACQ 
scores, making it impossible to make comparisons
17,28-30
. Two studies (one using ACT and 
one using ACQ) found an improvement with CPAP, whereas one study (using ACT alone) 
found no significant improvement. Serrano-Pariente et al demonstrated significant 
improvement in patients with either moderate-severe asthma or severe OSA at baseline
20
.  
However it is important to note that a clinically significant improvement in mean ACQ(≥0.5) 
was not reached. Shaarawy et al
16
 looked at fifteen poorly controlled asthmatics (ACT≤17 at 
baseline) and found no improvement in ACT scores after CPAP. Shaarawy et al studied a 
population with less severe OSA (mean AHI 23.5) compared to Serrano-Pariente et al (46.3) 
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and this could potentially account for these findings. Kauppi et al was the only study to 
demonstrate both a clinically and statistically significant improvement in ACT with CPAP. In 
this study, poor ACT scores at baseline were significant predictors of clinical improvement in 
ACT but severity of OSA was not a predictor
20
.  
 
Meta-analysis of FEV1(% predicted) measurements pre- and post-CPAP demonstrated no 
significant improvement with CPAP. The clinical importance of this is unclear as asthmatics 
have variable lung function and a proportion of severe asthmatics have fixed airflow 
obstruction. Lung function does not correlate with measures of asthma control in 
asthmatics with fixed airflow obstruction. Only two studies reported the FEV1/FVC ratio, 
which is a measure of airflow obstruction and none of the studies adjusted for patients with 
fixed airflow obstruction. This makes clinical interpretation of these results difficult because 
improvement in FEV1 would only be expected to reduce symptoms and measures of control 
in those without chronic fixed airflow obstruction
31
. Chan et al found a significant 
improvement in pre-bronchodilator PEFR but this was a relatively short study of only two 
weeks, and formal spirometry was not recorded
32
. Interestingly Wang et al
18
 when looking 
retrospectively at serial lung function pre- and post-initiation of CPAP, found that CPAP 
significantly reduced annual FEV1 in asthmatics with severe OSA compared to mild-
moderate OSA and no-OSA
18
. Serrano-Pariente et al found FENO to be significantly reduced 
after six months of CPAP
14
. However, non-asthmatic patients with OSA can have elevated 
FENO levels
6
 potentially attributable to upper airway inflammation secondary to repetitive 
upper airway obstruction. FENO has been shown to reduce after CPAP therapy in non-
asthmatics with OSA
6
, although this effect has not been shown in all studies. Another 
important factor is that cigarette smokers were included in this study. Cigarette smoke is 
known to affect FENO
33
. This makes interpretation of this result in one study difficult.  
 
CPAP therapy can improve quality of life in patients with moderate-severe OSA, and it is 
logical that this can also impact on asthma related quality of life (AQLQ) and the 
improvement that has been seen in this review. It is difficult to fully separate quality of life 
improvements seen as a result of treating OSA, from improvements as a result of reduced 
asthma symptoms. This review has found conflicting evidence with regards to asthma 
control (ACQ) when CPAP treatment is used for co-existing OSA. Potential reasons for this 
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include that CPAP may be poorly tolerated, particularly in severe asthma. The CPAP masks 
are recognised as being claustrophobic for some people, and this effect may be exacerbated 
in asthmatics who struggle with nocturnal symptoms of breathlessness and awakenings due 
to their asthma. Patients who feel reliant on medication at night might be concerned that 
the CPAP mask would make it harder to use their inhalers. 
 
This systematic review’s key strength is that it includes all study populations of asthmatics 
with co-existing OSA that have received CPAP treatment. We were able to evaluate a 
number of different asthma-related clinical outcomes including quality of life scores, asthma 
control/symptoms, asthma severity and lung function/physiological measures. Meta-
analysis enabled pooled results of asthma quality of life scores and lung function. 
Nevertheless, limitations include the small number of studies currently available, and 
heterogeneity of outcome measurements meant that meta-analysis was only possible in 
two of the clinical outcomes. Furthermore the individual studies did not report variability of 
change from pre- to post-CPAP values, so to enable meta-analysis the pre- and post-CPAP 
groups had to be analysed as independent groups which may have resulted in an over-
estimate of variability in each study. However, because we assumed greater variability than 
was present this is unlikely to have affected the overall trend of results as the improvement 
seen in AQLQ will still be at least as statistically significant as the result calculated. The lack 
of placebo-controlled studies should also be carefully considered when interpreting the 
results of this review. The placebo effect is well recognised within medical trials, and the 
CPAP device itself could act as powerful visual reminder for patients that they are receiving 
treatment.  
 
Conclusion 
In summary, this systematic review has demonstrated that CPAP treatment can improve 
asthma related quality of life and this effect appears more pronounced in severe OSA or 
poorly controlled asthma. Asthma symptoms and severity of asthma have also been shown 
to improve with CPAP but studies using standardised methods of measuring asthma control 
(such as ACQ) are conflicting. Multi-centre randomised placebo-controlled studies are 
needed to fully evaluate the impact of CPAP on asthma related symptoms and quality of life 
in patients with co-existing OSA. Such studies should include a range of severity for both 
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asthma and OSA, as the literature implies that the impact is greatest in more severe OSA 
and more severe asthma. Studies that assess clinical outcomes measures such as the ACQ 
and AQLQ (which are commonly used in clinical practice) would be of most benefit in this 
setting.  
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Table 1: Asthma-Related Quality of Life  
Study Population Asthma Severity OSA severity Clinical 
Measurement 
CPAP duration Outcome  
Lafond et al. Eur Respir J 
2007;29:307-311
34,35
 
N=20 
 
Completed follow 
up and compliant 
with CPAP 
(≥4 hours/night) 
“Stable” asthma- 
Occasional respiratory 
symptoms and absence 
of exacerbation or 
change in maintenance 
therapy in the preceding 
month 
Apnoea Hypopnoea 
Index (AHI)≥15 
 
Mean pre-CPAP 
AHI=48.1±23.6 
AQLQ 6 weeks  
 
 
Significant improvement in AQLQ; 5.0±1.2 to 5.8±0.9, p=0.001 
 
At baseline, AQLQ was inversely correlated with patients BMI (rho= -0.5, p=0.02). Following 
CPAP, the AQLQ positively correlated with BMI (rho=0.5, p=0.03) and AHI at baseline 
(rho=0.5, p=0.03) 
 
Following CPAP, the BMI was correlated with the improvement in the emotional 
(rho=0.5,p=0.02) and environmental domains (rho=0.5, p=0.01) of AQLQ 
 
The AHI at baseline was correlated with improvement in the symptomatic (rho=0.6, p=0.01), 
emotional (rho=0.6, p=0.01) and environmental domains (rho=0.5, p=0.05)  
 
Serrano-Pariente et al. 
Allergy 2016;72(5):802-
812
14,25
 
N=99  
 
82 completed follow 
up 
 
12/82 non-
compliant with 
CPAP  
(<4hours/night) 
N=28, intermittent-mild 
persistent asthma 
 
N= 71, moderate-severe 
persistent asthma 
Moderate-severe OSA 
with Respiratory 
Disturbance Index 
(RDI) ≥20 
 
Mean pre-CPAP RDI= 
46.3±20.8 
 
 
Mini AQLQ  6 months 
 
 
Significant improvement in mini AQLQ; 
5.12±1.38 to 5.63±1.17,p=0.009 
 
Asthma Severity 
Intermittent mild asthma; 5.77±0.93 to 6.04±0.85, p=0.303 
Mod-severe asthma; 4.87±1.45 to 5.48±1.24, p=0.012 
 
OSA Severity 
RDI≤30; 5.23±1.44 to 5.68±1.41, p=0.324 
RDI>30; 5.08±1.37 to 5.62±1.11, p=0.013 
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Table 2: Asthma Control & Symptoms 
Study Population Asthma Severity OSA Severity CPAP 
Duration 
Clinical Measurement Outcome 
Chan et al. Am Rev Respir Dis 
1988; 137:1502-1504
28
 
 
N=8 (asthma and 
OSA) 
1=No OSA 
Asthma with frequent 
nocturnal asthma attacks 
(previous respiratory 
arrest in 3 patients) 
AHI >5 
All had symptoms of 
snoring/nocturnal 
upper airway 
obstruction  
2 weeks  Asthma symptoms and 
bronchodilator requirements 
All 9 patients in this study showed marked improvement in nocturnal and 
daytime asthma symptoms, with reduced bronchodilator requirements.  
 
Ciftci et al. Respiratory Medicine 
2005;99:529-534
30
 
 
N=16 completed 
study  
 
(n=19 enrolled) 
≥1 nocturnal or early 
morning awakening due to 
asthma despite optimal 
treatment as per GINA 
guidelines 
AHI≥15 
Nasal CPAP 
Habitual snorers 
 
≥4/hours night CPAP 
compliance  
2 months Night time asthma symptom 
scores 
0: No symptoms 
1: ≤2 times/month 
2: >2 times/month 
3: <1 times/week 
4: Frequent 
Improved significantly after CPAP treatment from 2.19±1.07 to 1.44±1.15, 
p=0.04    
 
Guilleminault et al. Eur Respir J 
1988;1:902-907
29
 
 
N=10 (group A) 
 
(Group B excluded 
as not clearly OSA) 
 
Group A) Overweight 
middle aged asthmatic 
men with frequent 
nocturnal asthma attacks 
(N=10) 
 
 
RDI= 51±13 6-9 months Number of asthma attacks The number of nocturnal asthma attacks improved  
The frequency of daytime asthma attacks did not change 
 
Kauppi et al. Sleep Breath 
2016:20;1217-1224
20
 
N=152 
 
Mean compliance 6 
hours/day (SD 2.5) 
but range  0-10.2 
hrs/day 
Unknown Respiratory Event 
Index (REI) >15/h or  
5-14 and symptoms 
of OSA 
CPAP 
>3months 
(before CPAP 
initiation/retr
ospective and 
last 4 weeks) 
 
Mean 
duration of 
CPAP  5.7 
years (SD 4.7) 
 
ACT 
 
 
 
 
 
 
 
 
 
 
%patients using rescue 
medication daily 
 
Night-time symptoms 
Significant improvement in ACT; 
15.35(SD 5.3) to 19.8(SD 4.6), p<0.001 
- Significant correlation between values of ACT at baseline and those of 
asthma severity (visual analogue score) at baseline (r(102)=-0.721,p=0.000) 
-Patients that were female, lower baseline ACT and higher VAS severity 
score at baseline more likely to have clinically significant change in ACT 
(≥3). A slight decrease in weight (mean -1.6kg) during follow up was 
associated with a significant increase in ACT, p=0.007 
- Regression analysis showed female gender, baseline BMI, baseline ACT 
were significant predictors of ACT modifications. 
 
%patients using rescue medication daily; 
Reduced from 36 to 8% (p<0.001) 
 
 
Night-time symptoms; 
% of patients reporting no night-time symptoms increased from 28% to 
55% (p<0.001) 
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Serrano-Pariente. J. Allergy 
2016;72(5):802-812
14,27,36
 
N=99  
 
82 completed follow 
up 
 
12/82 non-
compliant with 
CPAP  
(<4hours/night) 
N=28, intermittent-mild 
persistent  
 
N= 71, moderate-severe 
persistent  
 
 
Moderate-severe 
OSA with RDI ≥20 
 
 
Mean pre-CPAP 
RDI= 46.3±20.8 
 
 
6 months  
 
 
Asthma Control 
Questionnaire (ACQ) 
 
 
 
 
 
Well-controlled asthma  
 
 
Asthma exacerbation 
frequency 
Significantly improved mean ACQ; 
1.39±0.91 to 1.0±0.78, p=0.003 
Asthma Severity 
Intermittent-Mild; 0.88±0.54 to 0.71±0.45, p=0.226 
Mod-severe;1.58±0.95 to 1.11±0.85, p=0.003 
OSA Severity 
RDI≤30; 1.47±0.88 to 1.02±0.88, p=0.113 
RDI>30; 1.36±0.92 to 0.99±0.76, p=0.012 
% asthmatics well-controlled; 
Percentage of patients with well-controlled asthma (ACQ≤0.75) increased 
from 28% to 38%. Percentage of patients with not well-controlled 
asthma(ACQ≥1.5) decreased from 41% to 17% (p=0.006) 
Asthma Exacerbation Frequency: 
The percentage of patients with at least one exacerbation decreased from 
35.4%(n=35) to 17.2%(n=17), p=0.015 
 
Shaarawy et al. Egyptian Journal 
of Chest Diseases and 
tuberculosis 2013;62 (1):183-
187
16,37, 
 
N=15 (completed 
follow up) 
Uncontrolled despite 
optimal treatment  
-ACT≤17 in last 4 weeks 
 
 
AHI>5/h 
 
Mean pre-CPAP 
AHI=23.5±10.9  
 
6 weeks  Asthma Control Test (ACT) 
 
 
No significant improvement; 
13.97±3.52 to 14.1±3.97, p>0.05 
 
 
 
Shaker et al. Egyptian Journal of 
Chest Disease and Tuberculosis 
2017;293-298
17
 
N=12 2 (16.7%) moderate-
persistent asthma 
10(83.3%) severe-
persistent asthma (GINA) 
AHI>5 
Mean AHI and 
compliance with 
CPAP not reported 
3 months 
CPAP 
Number of patients with 
daytime or night-time 
asthma symptoms   
 
Daytime symptoms; 11 (91.7%) pre-CPAP to 5(41.7%) post-CPAP, p=0.009 
Night-time symptoms; 11 (91.7%) pre-CPAP to 4 (33.3%) post-CPAP, 
p=0.003 
Teodorescu et al. J Asthma 
2012;49(6):620-628 
 
 
 
 
 
N=136 with asthma 
and OSA 
(75 using CPAP) 
Unclear Unknown-previous 
OSA (diagnosed by 
PSG) documented in 
notes 
Unknown Daytime and night-time 
asthma symptoms 
Asthma symptoms 
>2days/week: “persistent 
daytime symptoms” 
 
Asthma symptoms>2 
nights/month: “persistent 
night time symptoms” 
CPAP was associated with lower odds for persistent daytime asthma 
symptoms 0.5(0.25-1.00), p=0.049 but not night-time symptoms 0.62(0.31-
1.22),p=0.16.  
Relationships strengthened when adjusted for obesity 
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Wang et al. BMC Pulmonary 
Medicine 2017;17
18
  
 
N=13 with severe 
OSA – pre- and 
post-CPAP  
(21 non-compliant) 
 
N=77 total 
N=67 with asthma 
and OSA 
Not known Mild-Moderate 
OSA(≥5 AHI≤30); 
N=33 Severe OSA 
(AHI>30); N=  34  
 
N= 10 (no OSA) 
CPAP (5 year 
follow up) 
 
 
Compliance 
>4hours for 5 
days of wk 
No. of A&E visits for asthma Non-significant reduction in number of A&E visits per/year in severe OSA 
patients treated with CPAP; 0.52±0.62 to 0.35±0.52, p=0.058 
 
 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Table 3: Asthma Severity 
Study Population Asthma Severity OSA Severity CPAP Duration Measurement Intervention Outcome 
Kauppi et al. Sleep Breath 
2016:20;1217-1224
20
 
N=152 
 
Compliance with 
CPAP 6hrs/night (SD 
2.4) 
Unknown 
Self-reported using 
visual analogue 
scale 
REI>15/h or  5-14 
and symptoms of 
OSA 
CPAP >3months (before 
CPAP initiation/retrospective 
and last 4 weeks) 
 
Mean duration 5.7 years (SD 
4.7) 
 
Self-reported 
asthma severity 
-Visual analogue 
score; (0=no 
symptoms to 
100=severe asthma 
symptoms) 
CPAP >3months (before 
treatment and last 4 weeks) 
Significantly reduced from 48.3(29.6) to 
33.1(27.4), p<0.001 
Shaker et al. Egyptian Journal of 
Chest Disease and Tuberculosis 
2017;293-298
17
 
N=12 2 (16.7%) 
moderate-
persistent asthma 
10(83.3%) severe-
persistent asthma 
(GINA) 
AHI>5 
Mean AHI and 
compliance with 
CPAP not reported 
3 months CPAP Number of patients 
with “Difficult to 
control asthma”  
(asthma that could 
not be controlled 
with high dose ICS 
and LABA/other 
controller 
medication) 
3 months CPAP Significantly improved post CPAP;  
10 (83.3%) to 3 (25%), p=0.004 
 
Teodorescu  M et al. Sleep 
Disord.;2013:251567
19
 
 
 
N=140 
(75 using CPAP) 
Asthma Severity 
Step (NAEPP) 
 
Severe asthma; 
76(49%) older 
subjects 
 
257 (39%) younger 
subjects 
Unknown CPAP compared to no CPAP 
treatment of OSA 
Asthma severity 
step – Measured as 
per NAEPP 
guidelines 
CPAP compared to no CPAP 
treatment of OSA 
In older subjects, CPAP was associated with 
reduced likelihood of worse asthma step by 
86% (0.14(0.04-0.56), p=0.005, and of 
severe asthma by 91% (0.09(0.02-0.49), 
p=0.005.  
 
In younger subjects, CPAP attenuated the 
likelihood of worse asthma step by 58% 
(0.42(0.20-0.88), p=0.02 and that of severe 
asthma by 57% (0.43(0.18-1.03), p=0.06 
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Table 4: Lung Function and physiological measurements 
Study Population Asthma severity OSA severity CPAP Duration  Clinical measurement  Outcome 
Bonay et al. 
Respiratory 
Medicine 2003; 97: 
830-834
38
 
 
N=15 (asthma) 
 
 
22=Controls 
13=COPD 
 
 
Not known 
 
Mean AHI pre 
CPAP 47±27 in 
asthma group 
17±8 months of 
nasal CPAP 
 
Compliance=5.9
±0.9h/night 
FEV1  
FEV1/FVC 
No significant difference in FEV1, FEV1/FVC ratio or FEF50, FEF25 
or FEF25-75 following 17±8months of CPAP in asthma group. 
However- in control group; significant reduction in FEV1 p<0.05 
and FEV1/FVC, p<0.05 noted.   
 
 
PaO2 Significantly improved; 69±17 to 75±9mmHg,n=13,p<0.05 
PaCO2 Significantly reduced; 
45±6 to 43±5mmHg,n=13,p<0.05 
Chan et al. Am Rev 
Respir Dis 1988; 
137:1502-1504
28
 
 
N=8 (with 
asthma and 
OSA) 
1=No OSA 
Asthma with frequent 
nocturnal asthma 
attacks (previous 
respiratory arrest in 3 
patients) 
AHI >5 
All had symptoms 
of 
snoring/nocturnal 
upper airway 
obstruction  
2 weeks  Peak Expiratory Flow Rates 
(PEFR) 
Mean pre-bronchodilator PEFR was significantly higher during 
CPAP period than control periods both in the morning (p<0.05) 
and evening (p<0.02).  
 
Ciftci. T. et al. 
Respiratory 
Medicine 
2005;99:529-534
30
 
 
N=16 
completed 
study (n=19 
enrolled, 
1=intolerance, 
2=insufficient 
CPAP use),  
≥1 nocturnal or early 
morning awakening due 
to asthma despite 
optimal treatment as 
per GINA guidelines 
AHI≥15 
Nasal CPAP 
Habitual snorers 
 
≥4/hours night 
CPAP compliance  
2 months 
 
FEV1% predicted No significant change; 70.25±21.17 to 71.25±21.85, p=0.64 
FEV1/FVC No significant change; 66.68±15.64 to 70.75±15.37, p=0.12 
Lafond et al. Eur 
Respir J 
2007;29:307-311
34
 
N=20 
 
Completed 
follow up and 
compliant with 
CPAP >4 
hours/night 
“Stable” asthma- 
Occasional respiratory 
symptoms and absence 
of exacerbation or 
change in maintenance 
therapy in the preceding 
month 
AHI≥15 
 
Mean pre-CPAP 
AHI=48.1±23.6 
6 weeks  FEV1 % predicted No significant difference; 82±13.6 to 80.4±13.6 
 
20% fall in FEV1 (≤8mgmL 
PC20) to methacholine 
No significant difference post CPAP; PC20 2.2 (95% CI 1.3-3.5) to 2.5 
(95%CI 1.4-4.5), p=0.3 
-A reduction in PC20 was noted in 3 patients 
-Baseline PC20 was significantly higher in those that showed 
improvement to those that did not; 7.3mgmL
-1
 vs. 1.7, p=0.02  
 
Serrano-Pariente et 
al. Allergy 
2016;72(5):802-
812
14
 
N=99  
 
82 completed 
follow up 
 
12/82 non-
compliant with 
CPAP  
(<4hours/night) 
N=28, intermittent-mild 
persistent  
 
N= 71, moderate-severe 
persistent  
 
 
Moderate-severe 
OSA with RDI ≥20 
 
75.8% of 
population had 
RDI> 30 
 
Mean pre-CPAP 
RDI= 46.3 ± 20.8 
 
 
6 months  
 
 
FEV1% predicted No significant change; 83.6±17.6 to 83.6±16.6, p=0.977 
FENO Significant reduction; 
29.9±18.7 to 22±12.5, p=0.041 
GINA Guidelines 
≥12% and 200mL increase in 
FEV1 to SABA 
Significantly reduced post CPAP, (p<0.001) 
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Shaarawy et al. 
Egyptian journal of 
Chest Diseases and 
Tuberculosis 
2013;62 (1):183-
187
16
 
 
N=15 
(completed 
follow up) 
Uncontrolled despite 
optimal treatment  
-ACT≤17 in last 4 weeks 
 
 
AHI>5/h 
 
Mean pre-CPAP 
AHI=23.5±10.9  
 
6 weeks 
nocturnal CPAP 
FEV1% predicted No significant change; 60.1±6.9 to 61.2±6.2, p>0.05 
FEV1/FVC No significant change: 70.3 ± 8.2 to 72.5 ± 8.5, p>0.05 
Wang et al. BMC 
Pulm Med. 
2017;17(1):55-017-
0398-2.
18
 
N=77 total 
N=67 with 
asthma and 
OSA  
 
N=13 with 
severe OSA - 
pre and post 
CPAP  
(21 non-
compliant) 
 
Not known Mild-Moderate 
OSA(≥5 AHI≤30); 
N=33 
 
Severe OSA 
(AHI>30); N=34  
 
N= 10 (no OSA) 
CPAP (5 year 
follow up) 
 
Compliance 
>4hours for 5 
days of wk 
Annual FEV1 decline Annual decline of FEV1 in asthmatic patients with severe OSA was 
significantly increased compared to those with mild-mod OSA and 
to those without OSA(72±61.7mL vs. 41.9±45.3mL vs. 
24.3±27.5mL, p=0.046.). 
Decline in FEV1 was significantly lower after 2 years of CPAP 
(p=0.028) 
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Table 5: Summary of Results 
No
. 
Study Design Population Intervention Asthma Diagnosis OSA Diagnosis Outcomes 
1 Bonay et al. 
Respiratory 
Medicine 2003; 
97: 830-834
38
 
 
 
 
 
Quasi-
experimental 
N=50 
(15 asthma, 
13 COPD, 22 
Non-
Obstructive 
Airway 
Disease) 
17±8 months of 
nasal CPAP 
 
History or clinical 
evidence of asthma 
PSG 
AHI=47±34 
(whole 
population) 
 
AHI=47±27 
(asthma), non-
significant 
difference 
In entire study population (n=50), significant decreases in FEF50 (p<0.005), FEF25 (p<0.05), 
FEF25-75(p<0.005) observed. No significant changes in lung function in asthma or COPD 
group. Significant increase in PaO2 (p<0.01) (asthma and COPD) and reduction in 
PCO2(p<0.01) (asthma). 
 
Bronchial hyperresponsiveness occurred in 5/22 of the NOAD group 
2 Chan et al. Am 
Rev Respir Dis 
1988; 
137:1502-
1504
28
 
 
Quasi-
experimental 
N=8 (with 
asthma and 
OSA) 
1=No OSA 
2 weeks of CPAP; 
2wks of PEF pre-, 
during and post-
CPAP 
Unclear. All reported 
to have frequent 
nocturnal asthma 
attacks 
PSG 
AHI>5 
Mean pre-bronchodilator PEFR was significantly higher during CPAP period than control 
periods both in the morning (p<0.05) and evening (p<0.02). Marked improvement in 
nocturnal and daytime asthma symptoms. Reduced bronchodilator requirement during 
night and day. 
3 Ciftci et al. 
Respiratory 
Medicine 
2005;99:529-
534
30
 
 
Quasi-
experimental 
N=16 Nasal CPAP for 2 
months 
Unclear- GINA for 
optimisation only 
All had nocturnal 
asthma symptoms 
despite optimisation 
as per GINA guidelines 
PSG 
AHI≥15 
No significant different in pulmonary function tests (PFTs), but significant improvement in 
asthma night-time symptom scores (p=0.04) 
4 Guilleminault et 
al. Eur Respir J 
1988;1:902-
907
29
 
 
Quasi-
experimental 
N=10 (group 
A) 
 
 
6-9 months of 
CPAP 
 
Not stated 
 
Frequent nocturnal 
asthma attacks 
PSG 
RDI=51±13 
Group A only. Pre-CPAP: Mean 1 severe asthma attack during sleep every 17 days, 4 patients 
admitted to ICU at night >4 times/last year. Post- CPAP: no nocturnal asthma attacks, 
number of daytime asthma attacks unchanged. 
 
5 Kauppi et al. 
Sleep Breath 
2016:20;1217-
1224
20
 
Retrospective 
cross-
sectional 
study 
N=152 
asthma and 
OSA  
CPAP >3months 
(before CPAP 
initiation/retrospe
ctive and last 4 
weeks) 
 
Mean duration 
5.7years (SD 4.7) 
 
Self-reported 
physician diagnosis 
 
Asthma severity 
assessed by visual 
analogue score (0 for 
no symptoms to 100 
for severe symptoms) 
and also ACT 
Home  limited-
channel sleep 
study 
 
(REI>15/h or 5-14 
with symptoms of 
OSA) 
Self-reported asthma severity decreased from 48.3(29.6) to 33.1(27.4) (p<0.001), and ACT 
score increased significantly from 15.35(5.3) to 19.8(4.6) p<0.001. % of patients using rescue 
medication daily reduced from 36 to 8% with CPAP (p<0.001) 
6 Lafond et al. Eur 
Respir J 
2007;29:307-
311
34
 
 
 
Quasi-
experimental 
N=20 6 weeks nocturnal 
CPAP 
ATS criteria (all had 
20% fall in FEV1 
≤8mgmL
-1
) 
 
All stable asthmatics  
PSG 
AHI≥15 
No significant changes in airway hyperresponsiveness after CPAP treatment. Asthma quality 
of life score improved from 5±1.2 to 5.8±0.9 (p=0.001) 
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7 Serrano-
Pariente et al. 
Allergy 
2016;72(5):802-
812
14
 
Quasi-
experimental 
N=99 
(82 
completed 
follow up) 
CPAP for 6 
months 
GINA Guidelines  
N=28, intermittent-
mild persistent 
asthma 
N= 71, moderate-
severe persistent 
asthma 
PSG (30%) 
Limited-channel 
sleep study (70%) 
 
Moderate-severe 
OSA with RDI ≥20 
ACQ decreased from 1.39±0.61 to 1.0±0.78 (p=0.003). %uncontrolled asthma decreased 
from 41.4% to 17.2%(=0.006), % participants with asthma attacks/6months reduced from 
35.4% to 17.2% (p=0.015), mAQLQ increased from 5.12±1.38 to 5.63±1.17 (p=0.009), 
significant improvements in GORD, rhinitis, bronchial reversibility, and exhaled nitric oxide 
(p<0.05) 
8 Shaarawy et al. 
Egyptian journal 
of chest 
diseases and 
tuberculosis 
2013;62 
(1):183-187
16
 
 
 
Quasi-
experimental 
N=15 6 weeks nocturnal 
CPAP 
Proven reversible 
airway obstruction 
with spirometry pre- 
and post-
bronchodilation. 
Uncontrolled despite 
optimal treatment 
(ACT of ≤17 in last 4 
weeks) 
 
PSG 
AHI>5/h 
(23.5±10.9 pre-
CPAP) 
 
No significant improvement in ACT (13.97±3.52 to 14.1±3.97, p>0.05) or FEV1% pred 
(60.1±6.9 to 61.2±6.2, p>0.05) after CPAP 
9 Shaker et al. 
Egyptian 
Journal of Chest 
Diesease and 
Tuberculosis 
2017;293-298
17
 
Quasi-
experimental 
N=12 Patients with 
asthma and OSA 
had 3 months of 
CPAP 
GINA 
N=10/12 with 
“Difficult to control 
asthma”=could not be 
controlled with high 
dose ICS and 
LABA/other controller 
PSG 
 
AHI>5 
Significant improvement in daytime (p=0.009) and night-time (p=0.003) asthma symptoms, 
GORD symptoms (p=0.004), difficult to control asthma (p=0.004), FEV1% predicted (p=0.002) 
and FEV1/FVC ratio (p=0.003) 
10 Teodorescu  M 
et al. Sleep 
Disord.;2013:25
1567
19
 
 
 
 
Cross-
sectional 
questionnaire
-based study 
N=140 
(75 using 
CPAP)  
CPAP versus no 
CPAP treatment in 
asthma and co-
existing OSA 
“Specialist-diagnosed 
and managed” 
Severity step as per 
National Asthma 
Education and 
Prevention 
Programme (NAEPP) 
guidelines 
Previous PSG 
diagnosis in 
medical notes 
(and use of CPAP). 
In older subjects, CPAP was associated with reduced likelihood of worse asthma step by 86% 
(0.14(0.04-0.56), p=0.005), and of severe asthma by 91% (0.09(0.02-0.49), p=0.005).  
In younger subjects, CPAP attenuated the likelihood of worse asthma step by 58% 
(0.42(0.20-0.88), p=0.02) and that of severe asthma by 57% (0.43(0.18-1.03), p=0.06) 
 
 
11 
 
Teodorescu et 
al. J Asthma 
2012;49 (6): 
620-628 
 
Cross-
sectional 
questionnaire 
based study 
N=136 with 
asthma and 
OSA 
(75 using 
CPAP) 
CPAP versus no 
CPAP treatment  
Asthma diagnosed by 
academic specialist 
(based on ATS criteria) 
Severity as per NAEPP 
guidelines  
Review of medical 
records for 
previous diagnosis 
CPAP was associated with lower odds for persistent daytime asthma symptoms (0.5(0.25-
1.00), p=0.049) but not night-time symptoms (0.62(0.31-1.22),p=0.16).  
Relationships strengthened when adjusted for obesity 
12 Wang et al. 
BMC Pulmonary 
Medicine 
2017;17
18
 
 
 
Retrospective 
study- review 
of medical 
records 
N=77 total 
N=67 with 
asthma and 
OSA  
 
N=13 with 
severe OSA  
CPAP for 5 years ATS PSG 
10=no OSA 
(AHI<5) 
33=mild-
moderate OSA 
(>5AHI≤ 30) 
34=severe 
OSA(AHI>30) 
Annual decline of patients with severe OSA was significantly accelerated compared to 
patients with mild-moderate OSA and those without OSA (p=0.046). Annual decline in FEV1 
was significantly lower after CPAP initiated (p=0.028).  
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Figure 1: Mechanistic effect of CPAP improving asthma in co-existing OSA 
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Figure 2: PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
EMBASE and MEDLINE 
literature search: 128 articles 
113 articles selected after 
review of title  
24 articles selected for full text 
review 
89 excluded after abstract 
review: 
50 abstract only, 21 reviews, 
5 case reports, 3 letters, 1 
editorial, 9 did not meet 
inclusion/exclusion criteria 
 
15 excluded after title 
review (6 paediatric, 9 
irrelevant) 
12 articles included in 
systematic review 
9 excluded as per 
inclusion/exclusion after review 
of full text 
3 articles not available after 
review of British Library 
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Figure 3: Meta-Analysis of Clinical Outcomes pre and post CPAP 
 
a) Asthma related quality of life (AQLQ/mini-AQLQ)  
 
 
b) Lung Function (FEV1% predicted) 
 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Figure 4: Risk of bias for quasi-experimental studies 
A) Risk of bias graph, B) Risk of bias summary 
 
 
 
 
A) 
B) 
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Highlights 
- CPAP treatment of co-existing OSA can improve asthma-related quality of life 
- Asthma symptoms and severity of asthma have also been shown to improve with CPAP, 
but studies using standardised methods of measuring asthma control (such as ACQ) are 
conflicting 
- Multi-centre placebo-controlled studies are needed to fully evaluate the impact of CPAP 
treatment of co-existing OSA on asthma-related  clinical outcomes 
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